text:
Generic Name: botulinum toxin type a
Dosage Form: injection, powder, lyophilized, for solution
Postmarketing reports indicate that the effects of Dysport® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.
Cervical Dystonia
Dysport® (abobotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients.
Glabellar Lines
Dysport® (abobotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients < 65 years of age.
Dysport Dosage and Administration
The potency Units of Dysport® are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport® cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [see Description (11)].
Reconstitution instructions are specific for each of the 300 Unit vial and the 500 Unit vial. These volumes yield concentrations specific for the use for each indication.
Cervical Dystonia
The recommended initial dose of Dysport® for the treatment of cervical dystonia is 500 Units given intramuscularly as a divided dose among affected muscles in patients with or without a history of prior treatment with botulinum toxin. (A description of the average Dysport® dose and percentage of total dose injected into specific muscles in the pivotal clinical trials can be found in Table 5 of Section 14.1, Clinical Studies – Cervical Dystonia.) Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Clinical studies with Dysport® in cervical dystonia suggest that the peak effect occurs between two and four weeks after injection. Simultaneous EMG-guided application of Dysport® may be helpful in locating active muscles not identified by physical examination alone.
Dose Modification
Where dose modification is necessary for the treatment of cervical dystonia, uncontrolled open-label studies suggest that dose adjustment can be made in 250 Unit steps according to the individual patient's response, with re-treatment every 12 weeks or longer, as necessary, based on return of clinical symptoms. Uncontrolled open-label studies also suggest that the total dose administered in a single treatment should be between 250 Units and 1000 Units. Re-treatment, if needed, should not occur in intervals of less than 12 weeks. Doses above 1000 Units have not been systematically evaluated.
2.1.1 Special Populations
Adults and elderly
The starting dose of 500 Units recommended for cervical dystonia is applicable to adults of all ages [see Use in Specific Populations (8.5)].
The safety and effectiveness of Dysport® in the treatment of cervical dystonia in pediatric patients less than 18 years of age has not been assessed [see Warnings and Precautions (5.2)].
2.1.2 Instructions for Preparation and Administration
Dysport® is supplied as a single-use vial. Each 500 Unit vial of Dysport® is to be reconstituted with 1 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution of 500 Units per mL. Each 300 Unit vial of Dysport® is to be reconstituted with 0.6 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution equivalent to 250 Units per 0.5 mL.
Using an appropriately sized sterile syringe, needle and aseptic technique, draw up 1.0 mL or 0.6 mL of sterile, 0.9% Sodium Chloride Injection USP (without preservative) for 500 and 300 Unit vials, respectively. Insert the needle into the Dysport® vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no vacuum is observed. Swirl gently to dissolve. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Reconstituted Dysport® should be a clear, colorless solution, free of particulate matter, otherwise it should not be injected.
Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach an appropriately sized new sterile needle.
Once reconstituted, Dysport® should be stored in a refrigerator at 2–8°C (36–46°F) protected from light and used within 24 hours. Do not freeze reconstituted Dysport®. Discard the vial and needle in accordance with local regulations.
Glabellar Lines
The dose of Dysport® for the treatment of glabellar lines is a total of 50 Units given intramuscularly in five equal aliquots of 10 Units each to achieve clinical effect (see Figure 1).
2.2.1 Special Populations
A total dose of 50 Units of Dysport®, in five equal aliquots, should be administered to achieve clinical effect.
The clinical effect of Dysport® may last up to four months. Repeat dose clinical studies demonstrated continued efficacy with up to four repeated administrations. It should be administered no more frequently than every three months. When used for re-treatment, Dysport® should be reconstituted and injected using the same techniques as the initial treatment.
Dysport® for glabellar lines is not recommended for use in pediatric patients less than 18 years of age [see Warnings and Precautions (5.2)].
2.2.2 Instructions for Preparation and Administration
Dysport® is supplied as a single-use vial. Each 300 Unit vial of Dysport® is to be reconstituted with 2.5 mL of 0.9% Sodium Chloride Injection USP (without preservative) prior to injection. The concentration of the resulting solution will be 10 Units per 0.08 mL to be delivered in five equally divided aliquots of 0.08 mL each. Dysport® may also be reconstituted with 1.5 mL of 0.9% Sodium Chloride Injection USP (without preservative) for a solution of 10 Units per 0.05 mL to be delivered in five equally divided aliquots of 0.05 mL each.
Using an appropriately sized sterile syringe, needle and aseptic technique, draw up 2.5 mL or 1.5 mL of 0.9% Sodium Chloride Injection USP (without preservative). Insert the needle into the Dysport® vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no vacuum is observed. Swirl gently to dissolve. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Reconstituted Dysport® should be a clear, colorless solution, free of particulate matter otherwise it should not be injected.
Draw a single patient dose of Dysport® into a sterile syringe. Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach a 30 gauge needle.
Once reconstituted, Dysport® should be stored in a refrigerator at 2–8°C (36–46°F) protected from light and used within 24 hours. Do not freeze reconstituted Dysport®. Discard the vial and needle in accordance with local regulations.
2.2.3 Injection Technique
Glabellar facial lines arise from the activity of the lateral corrugator and vertical procerus muscles. These can be readily identified by palpating the tensed muscle mass while having the patient frown. The corrugator depresses the skin creating a "furrowed" vertical line surrounded by tensed muscle (i.e., frown lines). The location, size, and use of the muscles vary markedly among individuals. Physicians administering Dysport® must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures.
Risk of ptosis can be mitigated by careful examination of the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), identification of lash ptosis, and evaluation of the range of lid excursion while manually depressing the frontalis to assess compensation.
In order to reduce the complication of ptosis, the following steps should be taken:
- Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes.
- Medial corrugator injections should be placed at least 1 centimeter above the bony supraorbital ridge.
- Ensure the injected volume/dose is accurate and where feasible kept to a minimum.
- Do not inject toxin closer than 1 centimeter above the central eyebrow.
To inject Dysport®, advance the needle through the skin into the underlying muscle while applying finger pressure on the superior medial orbital rim. Inject patients with a total of 50 Units in five equally divided aliquots. Using a 30 gauge needle, inject 10 Units of Dysport® into each of five sites, two in each corrugator muscle, and one in the procerus muscle (see Figure 1).
Figure 1
Dosage Forms and Strengths
Cervical Dystonia
Dysport® is supplied as:
- a single-use, sterile 500 Unit vial for reconstitution with 1 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution of 500 Units per mL.
- a single-use, sterile 300 Unit vial for reconstitution with 0.6 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution equivalent to 250 Units per 0.5 mL.
Glabellar Lines
Dysport® is supplied as:
- a single-use, sterile 300 Unit vial for reconstitution with 0.9% Sodium Chloride Injection USP (without preservative). Dysport® may be reconstituted with either 2.5 mL to yield a solution of 10 Units per 0.08 mL or with 1.5 mL to yield a solution of 10 Units per 0.05 mL.
Dysport® is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation [see Adverse Reactions (6.1), Description (11)].
This product may contain trace amounts of cow's milk protein. Patients known to be allergic to cow's milk protein should not be treated with Dysport®.
Dysport® is contraindicated for use in patients with infection at the proposed injection site(s).
Warnings and Precautions
Lack of Interchangeability between Botulinum Toxin Products
The potency Units of Dysport® are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport® cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [see Description (11)].
Spread of Toxin Effect
Post-marketing safety data from Dysport® and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects. The risk of the symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, and particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.
Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia
Treatment with Dysport® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [see Warnings and Precautions (5.2)].
Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.
Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients.
Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin [see Warnings and Precautions (5.2), Adverse Reactions (6.1), Clinical Pharmacology (12.2)].
Facial Anatomy in the Treatment of Glabellar Lines
Caution should be exercised when administering Dysport® to patients with surgical alterations to the facial anatomy, excessive weakness or atrophy in the target muscle(s), marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin [see Dosage and Administration (2.2.3)] or the inability to substantially lessen glabellar lines by physically spreading them apart [see Clinical Studies (14.2)].
Do not exceed the recommended dosage and frequency of administration of Dysport®. In clinical trials, subjects who received a higher dose of Dysport® had an increased incidence of eyelid ptosis.
Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport® [see Adverse Reactions (6.1)].
Human Albumin
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been reported for albumin.
Adverse Reactions
The following adverse reactions to Dysport® are discussed in greater detail in other sections of the labeling.
- Hypersensitivity [see Contraindications (4)]
- Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia [see Warnings and Precautions (5.3)]
- Spread of Effects from Toxin [see Warnings and Precautions (5.2)]
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating incidence rates.
Cervical Dystonia
The data described below reflect exposure to Dysport® in 357 cervical dystonia patients in 6 studies. Of these, two studies were randomized, double-blind, single treatment, placebo controlled studies with subsequent optional open label treatment in which dose optimization (250 to 1000 Units per treatment) over the course of 5 treatment cycles was allowed.
The population was almost entirely Caucasian (99.2%) with a median age of 51 years (range 18–82 years). Most patients (86.6%) were less than 65 years of age; 58.4% were women.
Common Adverse Events
The most commonly reported adverse events (occurring in more than 5% of patients who received 500 Units of Dysport® in the placebo controlled clinical trials) in cervical dystonia patients were muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation). Most adverse events were reported as mild or moderate in severity. Other than injection site reactions, most adverse events became noticeable about one week after treatment and lasted several weeks.
The rates of adverse events were higher in the combined controlled and open-label experience than in the placebo-controlled trials.
During the clinical studies, two patients (<1%) experienced adverse events leading to withdrawal. One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.
Table 1 compares the incidence of the most frequent treatment-emergent adverse events (TEAEs) from a single treatment cycle of 500 Units of Dysport® compared to placebo [see Clinical Studies (14.1)].
|Double-blind Phase
|System Organ Class
Preferred Term
|Dysport® 500 Units
|Any TEAE
|General disorders and administration site conditions
|Injection site discomfort
|Injection site pain
|Musculoskeletal and connective tissue disorders
|Muscular weakness
|Musculoskeletal pain
|Gastrointestinal disorders
|Dry mouth
|Nervous system disorders
|Infections and infestations
|Respiratory, thoracic and mediastinal disorders
|Eye Disorders*
Dose-response relationships for common adverse events in a randomized multiple fixed-dose study in which the total dose was divided between two muscles (the sternocleidomastoid and splenius capitis) are shown in Table 2.
|System Organ Class
Preferred Term
|Dysport® Dose
|250 Units
|500 Units
|1000 Units
|Any Adverse Event
|Dry Mouth
|Muscular Weakness
|Injection Site Discomfort
|Facial Paresis
|Eye Disorders
Injection Site Reactions
Injection site discomfort and injection site pain were common adverse events following Dysport® administration. These events were mainly of mild or moderate intensity.
Less Common Adverse Events
The following selected adverse events were reported less frequently (<5%).
Breathing Difficulties
Breathing difficulties were reported by approximately 3% of patients following Dysport® administration and in 1% of placebo patients in clinical trials during the double-blind phase. These consisted mainly of dyspnea and were generally mild in intensity. The median time to onset from last dose of Dysport® was approximately one week, and the median duration was approximately three weeks.
Other selected adverse events with incidences of less than 5% in the Dysport® 500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of Dysport®-treated subjects and 1% of placebo-treated subjects, and muscle atrophy in 1% of Dysport®-treated subjects and in none of the placebo-treated subjects.
Laboratory Findings
Subjects treated with Dysport® exhibited a small increase from baseline (0.23 mol/L) in mean blood glucose relative to placebo-treated subjects. This was not clinically significant among subjects in the development program but could be a factor in patients whose diabetes is difficult to control.
Electrocardiographic Findings
ECG measurements were only recorded in a limited number of subjects in an open-label study without a placebo or active control. This study showed a statistically significant reduction in heart rate compared to baseline, averaging about three beats per minute, observed thirty minutes after injection.
Glabellar Lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not be predictive of rates observed in practice.
In placebo-controlled clinical trials of Dysport®, the most frequently reported adverse events (≥2%) following injection of Dysport® were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis and nausea.
Table 3 reflects exposure to Dysport® in 398 subjects aged 19 to 75 who were evaluated in the randomized, placebo-controlled clinical studies that assessed the use of Dysport® for the temporary improvement in the appearance of glabellar lines [see Clinical Studies (14)]. Adverse events of any cause were reported for 48% of the Dysport®-treated subjects and 33% of the placebo-treated subjects. Treatment-emergent adverse events were generally mild to moderate in severity.
|Adverse Events by Body System
n=398 (%)*
n=496 (%)*
|Any Treatment-emergent Adverse Event
|191 (48)
|163 (33)
|Eye Disorders
|Eyelid Edema
|8 (2)
|Eyelid Ptosis
|6 (2)
|1 (<1)
|Gastrointestinal Disorders
|6 (2)
|5 (1)
|General Disorders and Administration Site Conditions
|Injection Site Pain
|11 (3)
|8 (2)
|Injection Site Reaction
|12 (3)
|2 (<1)
|Infections and Infestations
|38 (10)
|21 (4)
|Upper Respiratory Tract Infection
|12 (3)
|9 (2)
|8 (2)
|6 (1)
|Blood Urine Present
|6 (2)
|1 (<1)
|Nervous System Disorders
|37 (9)
|23 (5)
In the overall safety database, where some subjects received up to twelve treatments with Dysport®, adverse events were reported for 57% (1425/2491) of subjects. The most frequently reported of these adverse events were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).
Adverse events that emerged after repeated injections in 2–3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.
The incidence of eyelid ptosis did not increase in the long-term safety studies with multiple re-treatments at intervals ≥ three months. The majority of eyelid ptosis events were mild to moderate in severity and resolved over several weeks. [see Injection Technique (2.2.3)].
Post-marketing Spontaneous Reports
There is extensive post-marketing experience outside the U.S. for the treatment of glabellar lines. Adverse reactions are reported voluntarily from a population of uncertain size; thus, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-marketing use: vertigo, eyelid ptosis, diplopia, vision blurred, photophobia, dysphagia, nausea, injection site reaction, malaise, influenza-like illness, hypersensitivity, sinusitis, amyotrophy, burning sensation, facial paresis, dizziness, headache, hypoesthesia, erythema, and excessive granulation tissue.
As with all therapeutic proteins, there is a potential for immunogenicity.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies across products in this class may be misleading.
Cervical Dystonia
About 3% of subjects developed antibodies (binding or neutralizing) over time with Dysport® treatment. The significance of these antibodies is unknown since in the presence of binding and neutralizing antibodies some patients may continue to experience clinical benefit.
Glabellar Lines
Testing for antibodies to Dysport® was performed for 1554 subjects who had up to nine cycles of treatment. Two subjects (0.13%) tested positive for binding antibodies at baseline. Three additional subjects tested positive for binding antibodies after receiving Dysport® treatment. None of the subjects tested positive for neutralizing antibodies.
Drug Interactions
No formal drug interaction studies have been conducted with Dysport®.
Patients treated concomitantly with botulinum toxins and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should be observed closely because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport® may potentiate systemic anticholinergic effects such as blurred vision.
The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport®.
Pregnancy Category C
Dysport® produced embryo-fetal toxicity when given to pregnant rats at doses similar to or greater than the maximum recommended human dose (MRHD) of 1000 Units on a body weight (Units/kg) basis.
In an embryo-fetal development study in which pregnant rats received intramuscular injections daily (2.2, 6.6, or 22 Units/kg on gestation days 6 through 17) or intermittently (44 Units/kg on gestation days 6 and 12 only) during organogenesis, increased early embryonic death was observed with both dosing schedules. The no-effect dose for embryo-fetal developmental toxicity was 2.2 Units/kg (one-tenth the MRHD on a body weight basis). Maternal toxicity was seen at 22 and 44 Units/kg. In a pre-and post-natal development study in which female rats received 6 weekly intramuscular injections (4.4, 11.1, 22.2, or 44 Units/kg) beginning on day 6 of gestation and continuing through parturition to weaning, an increase in stillbirths was observed at the highest dose, which was maternally toxic. The no-effect dose for pre- and post-natal developmental toxicity was 22.2 Units/kg (approximately equal to the MRHD on a body weight basis).
There are no adequate and well-controlled studies in pregnant women. Dysport® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pediatric Use
Cervical Dystonia
Safety and effectiveness in pediatric patients have not been established [see Warnings and Precautions (5.2)].
Glabellar Lines
Dysport® is not recommended for use in pediatric patients less than 18 years of age.
Geriatric Use
Cervical Dystonia
There were insufficient numbers of patients aged 65 and over in the clinical studies to determine whether they respond differently than younger patients. In general, elderly patients should be observed to evaluate their tolerability of Dysport®, due to the greater frequency of concomitant disease and other drug therapy [see Dosage and Administration (2.1.1)].
Glabellar Lines
Of the total number of subjects in the placebo-controlled clinical studies of Dysport®, 8 (1%) were 65 and over. Efficacy was not observed in subjects 65 years and over [see Clinical Studies (14.2)]. For the entire safety database of geriatric subjects, although there was no increase in the incidence of eyelid ptosis, geriatric subjects did have an increase in the number of ocular adverse events compared to younger subjects (11% vs. 5%) [see Dosage and Administration (2.2)].
Excessive doses of Dysport® may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis [see Warnings and Precautions (5.2)]. Symptomatic treatment may be necessary.
Symptoms of overdose are likely not to be present immediately following injection. Should accidental injection or oral ingestion occur, the person should be medically supervised for several weeks for signs and symptoms of excessive muscle weakness or paralysis.
There is no significant information regarding overdose from clinical studies in cervical dystonia. Doses exceeding 1000 Units of Dysport® were rarely studied in clinical settings for any indication.
In the event of overdose, antitoxin raised against botulinum toxin is available from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. However, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration. In the event of suspected or actual cases of botulinum toxin poisoning, please contact your local or state Health Department to process a request for antitoxin through the CDC. If you do not receive a response within 30 minutes, please contact the CDC directly at 770-488-7100. More information can be obtained at http://www.cdc.gov/ncidod/srp/drugs/drug-service.html.
Dysport Description
Botulinum toxin type A, the active ingredient in Dysport® (abobotulinumtoxinA), is a purified neurotoxin type A complex produced by fermentation of the bacterium Clostridium botulinum type A, Hall Strain. It is purified from the culture supernatant by a series of precipitation, dialysis, and chromatography steps. The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins and non-toxin non-hemagglutinin protein.
Dysport® is supplied in a single-use, sterile vial for reconstitution intended for intramuscular injection. Each vial contains 500 or 300 Units of lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg lactose. Dysport® may contain trace amounts of cow's milk proteins [see Contraindications (4)].
One unit of Dysport® corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. The method for performing the assay is specific to Ipsen's product Dysport®. Due to differences in specific details such as vehicle, dilution scheme and laboratory protocols for various mouse LD50 assays, Units of biological activity of Dysport® are not interchangeable with Units of any other botulinum toxin or any toxin assessed with any other specific assay method [see Dosage Forms and Strengths (3)].
Dysport - Clinical Pharmacology
Mechanism of Action
Dysport® inhibits release of the neurotransmitter, acetylcholine, from peripheral cholinergic nerve endings. Toxin activity occurs in the following sequence: Toxin heavy chain mediated binding to specific surface receptors on nerve endings, internalization of the toxin by receptor mediated endocytosis, pH-induced translocation of the toxin light chain to the cell cytosol and cleavage of SNAP25 leading to intracellular blockage of neurotransmitter exocytosis into the neuromuscular junction. This accounts for the therapeutic utility of the toxin in diseases characterized by excessive efferent activity in motor nerves.
Recovery of transmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed.
The primary pharmacodynamic effect of Dysport® is due to chemical denervation of the treated muscle resulting in a measurable decrease of the compound muscle action potential, causing a localized reduction of muscle activity.
Nonclinical Toxicology
Carcinogenicity, Mutagenicity, Impairment of Fertility
Studies to evaluate the carcinogenic potential of Dysport® have not been conducted.
Genotoxicity studies have not been conducted for Dysport®.
Impairment of Fertility
In a fertility and early embryonic development study in rats in which either males (2.9, 7.2, 14.5 or 29 Units/kg) or females (7.4, 19.7, 39.4 or 78.8 Units/kg) received weekly intramuscular injections prior to and after mating, dose-related increases in pre-implantation loss and reduced numbers of corpora lutea were noted in treated females. Failure to mate was observed in males that received the high dose. The no-effect dose for effects on fertility was 7.4 Units/kg in females and 14.5 Units/kg in males (approximately one-half and equal to, respectively, the maximum recommended human dose of 1000 Units on a body weight basis).
Clinical Studies
Cervical Dystonia
The efficacy of Dysport® was evaluated in two well-controlled, randomized, double-blind, placebo controlled, single dose, parallel group studies in treatment-naïve cervical dystonia patients. The principal analyses from these trials provide the primary demonstration of efficacy involving 252 patients (121 on Dysport®, 131 on placebo) with 36% male and 64% female. Ninety-nine percent of the patients were Caucasian.
In both placebo controlled studies (Study 1 and Study 2), a dose of 500 Units Dysport® was given by intramuscular injection divided among two to four affected muscles. These studies were followed by long-term open label extensions that allowed titration in 250 Unit steps to doses in a range of 250 to 1000 Units, after the initial dose of 500 Units. In the extension studies, re-treatment was determined by clinical need after a minimum of 12 weeks. The median time to re-treatment was 14 weeks and 18 weeks for the 75th percentile.
The primary assessment of efficacy was based on the total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) change from baseline at Week 4 for both studies. The scale evaluates the severity of dystonia, patient perceived disability from dystonia, and pain. The adjusted mean change from baseline in the TWSTRS total score was statistically significantly greater for the Dysport® group than the placebo group at Weeks 4 in both studies (see Table 4).
|Study 1
|Study 2
500 Units
500 Units
|Baseline (week 0)
|Mean (SD)
|43.8 (8.0)
|45.8 (8.9)
|45.1 (8.7)
|46.2 (9.4)
|Week 4
|Mean (SD)
|30.0 (12.7)
|40.2 (11.8)
|35.2 (13.8)
|42.4 (12.2)
|Change from Baseline*
|-15.6 (2.0)
|-6.7 (2.0)
|-9.6 (2.0)
|-3.7 (1.8)
|Treatment difference
|95% confidence interval
|[-12.9 to -4.7]
|[-10.6 to -1.3]
|Week 8
|Mean (SD)
|29.3 (11.0)
|39.6 (13.5)
|Change from Baseline*
|-14.7 (2.0)
|-5.9 (2.0)
|Treatment difference
|95% confidence interval
|[-12.9 to -4.7]
Analyses by gender, weight, geographic region, underlying pain, cervical dystonia severity at baseline and history of treatment with botulinum toxin did not show any meaningful differences between groups.
Table 5 indicates the average Dysport® dose, and percentage of total dose, injected into specific muscles in the pivotal clinical trials.
|Number of patients injected per muscle*
|Dysport® Dose Injected
|Percentage of the total Dysport® Dose Injected
[Dysport® Units]
(min, max)
|75th percentile
[Dysport® Units]
(min, max)
|75th percentile
|125 Units
(50, 350)
|150 Units
|26.5 %
(10, 70)
|30.0 %
|Splenius capitis
|200 Units
(75, 450)
|250 Units
|40.0 %
(15, 90)
|50.0 %
|102.6 Units
(50, 300)
|150 Units
|20.6 %
(10, 60)
|30.0 %
|Levator scapulae
|105.3 Units
(50, 200)
|125 Units
|21.1 %
(10, 40)
|25.0 %
|Scalenus (medius and anterior)
|115.5 Units
(50, 300)
|150 Units
|23.1 %
(10, 60)
|30.0 %
|Semispinalis capitis
|131.6 Units
(50, 250)
|175 Units
|29.4 %
(10, 50)
|35.0 %
|150 Units
(100, 200)
|200 Units
|30.0 %
(20, 40)
|40.0 %
Glabellar Lines
Three double-blind, randomized, placebo-controlled, clinical studies evaluated the efficacy of Dysport® for use in the temporary improvement of the appearance of moderate to severe glabellar lines. These three studies enrolled healthy adults (ages 19-75) with glabellar lines of at least moderate severity at maximum frown. Subjects were excluded if they had marked ptosis, deep dermal scarring, or a substantial inability to lessen glabellar lines, even by physically spreading them apart. The subjects in these studies received either Dysport® or placebo. The total dose was delivered in equally divided aliquots to specified injection sites (see Figure 1).
Investigators and subjects assessed efficacy at maximum frown by using a 4-point scale (none, mild, moderate, severe).
Overall treatment success was defined as post-treatment glabellar line severity of none or mild with at least 2 grade improvement from Baseline for the combined investigator and subject assessments (composite assessment) on Day 30 (see Table 6). Additional endpoints for each of the studies were post-treatment glabellar line severity of none or mild with at least a 1 grade improvement from Baseline for the separate investigator and subject assessments on Day 30.
After completion of the randomized studies, subjects were offered participation in a two-year, open-label re-treatment study to assess the safety of multiple treatments.
|2 Grade Improvement
n/N (%)
n/N (%)
|58/105 (55%)
|0/53 (0%)
|37/71 (52%)
|0/71 (0%)
|120/200 (60%)
|0/100 (0%)
Treatment with Dysport® reduced the severity of glabellar lines for up to four months.
Study GL-1
Study GL-1 was a single dose, double-blind, multi-center, randomized, placebo-controlled study in which 158 previously untreated subjects received either placebo or 50 Units of Dysport®, administered in five aliquots of 10 Units (see Figure 1). Subjects were followed for 180 days. The mean age was 43 years; most of the subjects were women (85%), and predominantly Caucasian (49%) or Hispanic (47%). At Day 30, 55% of Dysport®-treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown (see Table 6).
In study GL-1, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the Dysport® group compared to the placebo group as assessed by both Investigators and subjects (see Table 7).
|Investigator's Assessment
|Subject's Assessment
Study GL-2
Study GL-2 was a repeat dose, double-blind, multi-center, placebo-controlled, randomized study. The study was initiated with two or three open-label treatment cycles of 50 Units of Dysport® administered in five aliquots of 10 Units Dysport® (see Figure 1). After the open-label treatments, subjects were randomized to receive either placebo or 50 Units of Dysport®. Subjects could have received up to four treatments through the course of the study. Efficacy was assessed in the final randomized treatment cycle. The study enrolled 311 subjects into the first treatment cycle and 142 subjects were randomized into the final treatment cycle. Overall, the mean age was 47 years; most of the subjects were women (86%) and predominantly Caucasian (80%).
At Day 30, 52% of Dysport®-treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown (see Table 6).
The proportion of responders in the final treatment cycle was comparable to the proportion of responders in all prior treatment cycles.
After the final repeat treatment with Dysport®, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the Dysport® group compared to the placebo group as assessed by both Investigators and subjects (see Table 8).
|Investigator's Assessment
|Subject's Assessment
Study GL-3
Study GL-3 was a single dose, double-blind, multi-center, randomized, placebo-controlled study in which 300 previously untreated subjects received either placebo or 50 Units of Dysport®, administered in five aliquots of 10 Units (see Figure 1). Subjects were followed for 150 days. The mean age was 44 years; most of the subjects were women (87%), and predominantly Caucasian (75%) or Hispanic (18%).
At Day 30, 60% of Dysport®-treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown (see Table 6).
In study GL-3, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the Dysport® group compared to the placebo group as assessed by both Investigators and subjects (see Table 9).
|Investigator's Assessment
|Subject's Assessment
Geriatric Subjects
In GL1, GL2, and GL3, there were 8 subjects aged 65 and older who were randomized to Dysport® 50 Units in 5 equal aliquots of 10 Units (4) or placebo (4). None of the geriatric Dysport® subjects were a treatment success at maximum frown at Day 30.
How Supplied/Storage and Handling
Dysport® for Injection is supplied in a sterile, single-use, 3 mL glass vial. Dysport® must be stored under refrigeration at 2–8°C (36–46°F). Protect from light.
Administer Dysport® within 24 hours of reconstitution; during this period reconstituted Dysport® should be stored under refrigeration at 2–8°C (36–46°F). Do not freeze after reconstitution.
Do not use after the expiration date on the vial. All vials, including expired vials, or equipment used with Dysport® should be disposed of carefully as is done with all medical waste.
Dysport® contains a unique hologram on the carton. If you do not see the hologram, do not use the product. Instead contact 1-855-463-5127.
Cervical Dystonia
- 500 Unit Vial
- Each vial contains 500 Units of freeze-dried abobotulinumtoxinA.
- Box containing 1 vial—NDC 15054-0500-1
- Box containing 2 vials—NDC 15054-0500-2
- 300 Unit Vial
- Each vial contains 300 Units of freeze-dried abobotulinumtoxinA.
- Box containing 1 vial—NDC 15054-0530-6
Glabellar Lines
- Each vial contains 300 Units of freeze-dried abobotulinumtoxinA.
- Box containing 1 vial—NDC 0299-5962-30
Patient Counseling Information
The physician should provide a copy of the FDA-Approved Patient Medication Guide and review the contents with the patient. Patients should be advised to inform their doctor or pharmacist if they develop any unusual symptoms (including difficulty with swallowing, speaking or breathing), or if any known symptom persists or worsens.
Patients should be counseled that if loss of strength, muscle weakness, blurred vision or drooping eyelids occur, they should avoid driving a car or engaging in other potentially hazardous activities.
Manufactured by:
Ipsen Biopharm Ltd.
Wrexham, LL13 9UF, UK
Distributed by:
Ipsen Biopharmaceuticals, Inc.
Basking Ridge, NJ 07920
Galderma Laboratories, L.P.
Fort Worth, TX 76177 USA
Dysport® (DIS-port)
Read the Medication Guide that comes with Dysport® before you start using it and each time Dysport® is given to you. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. You should share this information with your family members and caregivers.
What is the most important information I should know about Dysport®?
Dysport® may cause serious side effects that can be life threatening including:
- Problems breathing or swallowing
- Spread of toxin effects
These problems can happen within hours, or days to weeks after an injection of Dysport®. Call your doctor or get medical help right away if you have any of these problems after treatment with Dysport®:
- 1.
- Problems swallowing, speaking, or breathing. These problems can happen within hours, or days to weeks after an injection of Dysport® usually because the muscles that you use to breathe and swallow can become weak after the injection. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with Dysport®.
- People with certain breathing problems may need to use muscles in their neck to help them breathe. These patients may be at greater risk for serious breathing problems with Dysport®.
- Swallowing problems may last for several weeks. People who can not swallow well may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving Dysport® have the highest risk of getting these problems.
- 2.
- Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include:
- loss of strength and muscle weakness all over the body
- double vision
- blurred vision and drooping eyelids
- hoarseness or change or loss of voice (dysphonia)
- trouble saying words clearly (dysarthria)
- loss of bladder control
- trouble breathing
- trouble swallowing
These symptoms can happen within hours, or days to weeks after you receive an injection of Dysport®. These problems could make it unsafe for you to drive a car or do other dangerous activities. See "What should I avoid while receiving Dysport®?".
What is Dysport®?
Dysport® is a prescription medicine that is injected into muscles and used:
- to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults
- to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults younger than 65 years of age for a short period of time (temporary)
CD is caused by muscle spasms in the neck. These spasms cause abnormal position of the head and often neck pain. After Dysport® is injected into muscles, those muscles are weakened for up to 12 to 16 weeks or longer. This may help lessen your symptoms.
Frown lines (wrinkles) happen because the muscles that control facial expression are used often (muscle tightening over and over). After Dysport® is injected into the muscles that control facial expression, the medicine stops the tightening of these muscles for up to 4 months.
It is not known whether Dysport® is safe or effective in children under 18 years of age.
It is not known whether Dysport® is safe or effective for the treatment of other types of muscle spasms. It is not known whether Dysport® is safe or effective for the treatment of other wrinkles.
Who should not take Dysport®?
Do not take Dysport® if you:
- are allergic to Dysport® or any of the ingredients in Dysport®. See the end of this Medication Guide for a list of ingredients in Dysport®
- are allergic to cow's milk protein
- had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB)1, Botox®(onabotulinumtoxinA)1, or Xeomin®(incobotulinumtoxinA)1.
- have a skin infection at the planned injection site
What should I tell my doctor before taking Dysport®?
Tell your doctor about all your medical conditions, including if you:
- have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis or Lambert-Eaton syndrome). See "What is the most important information I should know about Dysport® ?"
- have allergies to any botulinum toxin product
- had any side effect from any botulinum toxin product in the past
- have or have had a breathing problem, such as asthma or emphysema
- have or have had swallowing problems
- have or have had bleeding problems
- have diabetes
- have or have had a slow heart beat or other problem with your heart rate or rhythm
- have plans to have surgery
- had surgery on your face
- have weakness of your forehead muscles (such as trouble raising your eyebrows)
- have drooping eyelids
- have any other change in the way your face normally looks
- are pregnant or plan to become pregnant. It is not known if Dysport® can harm your unborn baby
- are breast-feeding or planning to breast-feed. It is not known if Dysport® passes into breast milk
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal products. Using Dysport® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received Dysport® in the past.
Especially tell your doctor if you:
- have received any other botulinum toxin product in the last four months
- have received injections of botulinum toxin, such as Myobloc® (rimabotulinumtoxinB)1, Botox® (onabotulinumtoxinA)1 or Xeomin® (incobotulinumtoxinA)1 in the past; be sure your doctor knows exactly which product you received
- have recently received an antibiotic by injection
- take muscle relaxants
- take an allergy or cold medicine
- take a sleep medicine
Ask your doctor if you are not sure if your medicine is one that is listed above.
Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.
How should I take Dysport®?
- Dysport® is an injection that your doctor will give you
- Dysport® is injected into the affected muscles
- Your doctor may give you another dose of Dysport® after 12 weeks or longer, if it is needed
- If you are being treated for CD, your doctor may change your dose of Dysport®, until you and your doctor find the best dose for you
- The dose of Dysport® is not the same as the dose of any other botulinum toxin product
What should I avoid while taking Dysport®?
Dysport® may cause loss of strength or general muscle weakness, blurred vision, or drooping eyelids within hours to weeks of taking Dysport®. If this happens, do not drive a car, operate machinery, or do other dangerous activities. See "What is the most important information I should know about Dysport®?"
What are the possible side effects of Dysport®?
Dysport® can cause serious side effects. See "What is the most important information I should know about Dysport®?"
Other side effects of Dysport® include:
- dry mouth
- injection site discomfort or pain
- tiredness
- headache
- neck pain
- muscle pain
- eye problems: double vision, blurred vision, decreased eyesight, problems with focusing the eyes (accommodation), drooping eyelids, swelling of the eyelids
- allergic reactions. Symptoms of an allergic reaction to Dysport® may include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Tell your doctor or get medical help right away if you get wheezing or asthma symptoms, or if you get dizzy or faint
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Dysport®. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about Dysport®:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
This Medication Guide summarizes the most important information about Dysport®. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Dysport® that is written for healthcare professionals. For more information about Dysport® call 1-855-463-5127 or go to www.Dysport.com or www.DysportUSA.com.
What are the ingredients in Dysport®?
Active ingredient: (botulinum toxin Type A)
Inactive ingredients: human albumin, and lactose. Dysport® may contain cow's milk protein.
Revised October 2014
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Distributed by:
Ipsen Biopharmaceuticals, Inc.
Basking Ridge, NJ 07920
Galderma Laboratories, L.P.
Fort Worth, TX 76177 USA
- 1
- All trademarks are the property of their respective owners
PRINCIPAL DISPLAY PANEL - Vial Carton - 500 Units
Rx only
NDC Number: 15054-0500-1
1 Vial
for Injection
For intramuscular use
500 units/vial
PRINCIPAL DISPLAY PANEL - Vial Carton - 300 Units
Rx only
NDC Number: 15054-0530-6
1 Vial
for Injection
For intramuscular use
300 units/vial
botulinum toxin type a injection, powder, lyophilized, for solution
botulinum toxin type a injection, powder, lyophilized, for solution
|Labeler - Ipsen Biopharmaceuticals, Inc. (118461578)


text:
I've worked out the kinks in this pattern and am now happy to share it here. This is a super simple knit and purl design that has a great texture that would work well for both men and women. It would also work for children too. Vary the yarn and have a ball with it! I whole heartedly thank the Delaware Head Hugger Facebook family for helping me name this one.
As always, the pattern is free, but I do ask you to come to our Facebook page and like us and follow along with us as we deliver thousands of hats to people across the country. We're a friendly group - stop by, share your stories, post photos of your latest work or just say HI!
The pattern can be found as a PDF here. If you are having problems printing it, check your printer settings. You can usually chose to print in black and white or only print the pages that you want.
5-weight yarn – less than 100 yards

subset: commoncrawl


text:
Someone's got to stop her.
On Friday's episode of "The Bold and the Beautiful," Hope talks to Rick about Liam, while Brooke spreads the word about Taylor. Watch the sneak peek below.
Vote in our Thursday Throwback B&B Poll: Felicia's Secret. Watch a 90210 teaser video.
Join us on Twitter @soapoperafan and Facebook. Come tweet and Facebook with us about "The Bold And The Beautiful," all the other soap operas, "Dallas," "Glee," "Grey's Anatomy," "Pretty Little Liars," "Revenge," "Vampire Diaries," and "Venice The Series."
Header photo: CBS
- Candace Young


text:
Feb. 22, 2011
Matador Men's Volleyball Notes in PDF Format
Match #15
No. 1 USC Trojans (8-1, 8-1 MPSF) at Northridge Matadors (4-10, 3-6 MPSF)
Wednesday, February 23, 2011 - 7 p.m. PST
The Matadome - Northridge, Calif.
Live Stats: Gametracker (GoMatadors.com)
Live Audio: usctrojans.com
Match #16
No. 9 Pepperdine Waves (5-6, 3-6 MPSF) at Northridge Matadors (4-10, 3-6 MPSF)
Friday, February 25, 2011 - 7 p.m. PST
The Matadome - Northridge, Calif.
Live Stats: Gametracker (GoMatadors.com)
Live Audio: GoMatadors.com (Mark Schuermann - PBP)
After playing 10 of its first 14 matches on the road, Cal State Northridge (4-10, 3-6 MPSF) returns home this week to host top-ranked USC (8-1, 8-1 MPSF) and ninth-ranked Pepperdine (5-6, 3-6 MPSF). The Matadors and Trojans will square off Wednesday and CSUN and the Waves will tangle on Friday. Both matches begin at 7 p.m. in The Matadome. Wednesday's match against USC opens up a stretch where Northridge will play seven of its next eight matches in the friendly confines of home.
Jeff Campbell is in his 14th season as head coach with 216 career wins, the most in Northridge men's volleyball history. With the Matadors' 3-0 win at Long Beach State on Jan. 15, 2010, Campbell won his 195th match became the winningest coach in CSUN men's volleyball history surpassing John Price (194-158) who coached the Matador men for 12 seasons. Campbell has averaged over 23 wins per season over the last three seasons and has led the Matadors to at least 18 wins every season since 2003.
Follow Matador volleyball online at the official online home of Cal State Northridge athletics, www.GoMatadors.com. All Matador home matches and a majority of road matches will be broadcast live via Gametracker. In addition, select home and road matches will feature live audio. Fans can also follow the Matadors at Twitter.com/gomatadors and YouTube.com/northridgeathletics. Fans can also view and print the Matadors 2011 media guide online at GoMatadors.com. The guide features player information, photos, statistics and a complete men's volleyball history.
Despite splitting two matches last week, Cal State Northridge lost additional votes this week to remain unranked in the AVCA Coaches Top-15 Poll released Feb. 21. The Matadors, who earned a season-high 84 points Jan. 17, earned a season-low eight points in this week's poll down three points from last week. Northridge has now been unranked in three consecutive polls for the first time since the 1999 season. The Matadors had been ranked in the AVCA Top-15 for 155 consecutive weeks prior to Feb. 7. USC (8-1), Northridge's Wednesday opponent, received 15 of 16 first-place votes this week to retain the No. 1 spot for the seventh consecutive week. BYU (11-4) remained second, UC Santa Barbara (9-6) moved into third with Stanford (10-4) fourth and Ohio State (10-2) fifth. Long Beach State (7-5) is sixth this week followed by UC Irvine (8-6), UCLA (8-8), Pepperdine (5-6) and Hawai'i (6-7). This week's top-15 is rounded out by Penn State (11-3), Loyola-Chicago (9-3), UC San Diego (6-10), Lewis (10-3) and Pacific (6-9).
The Matadors will get their second opportunity this season to knock off a top-ranked team in USC on Wednesday. CSUN lost in straight sets to the No. 1 Trojans in the first chance on Jan. 12 at the Galen Center. USC will be the first number one team to visit The Matadome since the Matadors turned back then-No. 1 Stanford on April 2 of 2010. Northridge is now 4-21 in matches against teams ranked number one in the AVCA Top-15 poll dating back to the 2000 season. Prior to defeating Stanford last season, the Matadors had hosted three top-ranked teams since 2005, falling twice to UC Irvine (2006, 2007) and once to UCLA (2005).
Saturday's win at UC San Diego was important in more ways than one for the Matadors. The victory, CSUN's third in conference, kept the Matadors in the discussion for a possible MPSF Tournament berth. Northridge jumped from the MPSF cellar into a tie for eighth place with Friday's opponent, Pepperdine. The top eight teams qualify for the conference tournament which CSUN hasn't missed since the 2001 season. The win was also the Matadors' first on the road since defeating Pepperdine on Jan. 15 in Malibu and can possibly build some momentum as CSUN heads into a three-match homestand. Several Matadors recorded season and career-highs in the win as Matt Stork (Topanga, Calif.) had a career-best seven blocks (two solo) and a season-high 10 digs. Senior Kaleo Baxter (Kapaa, Hawai'i) posted a career-high 13 digs while Drew Staker (Las Vegas, Nev.) also stuffed a career-high seven UCSD attacks. Freshman Greg Faulkner (Los Angeles, Calif.) had season-highs of 11 kills and six blocks with two of those solo stuffs.
Junior setter Matt Stork posted Northridge's first double-double this season as he recorded 42 assists and 10 digs at UC San Diego on Saturday. The double-double was the sixth of Stork's career and his first since Feb. 3, 2010 when he had 56 assists and 12 digs in the Matadors' 3-2 win over No. 2 USC. Stork also continued his ascent up the Cal State Northridge career assists list. Stork, who surpassed 3,500 career assists with 24 helpers at No. 8 Penn State on Feb. 5, now has 3,624 career assists in 278 sets, an career average of 12.94 assists per game. Stork, who had his streak of 70 consecutive starts as the Matador setter snapped against UC Santa Barbara on Jan. 21, set a personal season-best with 1,626 assists (13.22 apg) as a sophomore in 2010. He had 1,588 assists (14.18) as a freshman.
Last week's matches at UC Irvine and UC San Diego concluded a stretch where the Matadors played 10 of their first 14 matches of the season on the road. Northridge will play seven of its next eight matches at home where the Matadors are 1-3 in four matches in The Matadome. After starting 1-5 in MPSF play, Northridge has won two of its last three to improve to 3-6 in conference with five MPSF matches at home over the next three weeks.
With the 3-1 win at UC San Diego, the Matadors and head coach Jeff Campbell kept win streaks intact. CSUN, which had not lost to UCSD since the 1988 season, won its 38th straight over the Tritons. Campbell has still never lost to UCSD in 25 career matches ... With wins over USC and Pepperdine this week, the Matadors can post a winning record in February after posting a 2-7 record in January. CSUN is 2-3 in the month of February heading into this week's matches ... Brandon Lebrock (Northridge, Calif.) and Tanner Nua (Palmdale, Calif.) each bounced back with solid efforts against UCSD on Saturday. Lebrock, who has been battling illness of late, had 11 kills against the Tritons, the first time he reached double figures in kills since putting down 12 at UCLA on Jan. 19. Nua matched his season-high with 13 kills and also matched his season-high with 17 points ... The Matadors improved to a perfect 3-0 when they out-hit their opponents but are 1-10 when they are out-hit ... Staker and Lebrock are the only two Matador players to have started all 14 matches this season ... As a team, the Matadors hit .200 at UC Irvine and .177 at UCSD which dropped their team hitting percentage this season to .220. CSUN has committed 52 more hitting errors that its opponents and have 113 fewer kills.
The Matadors and top-ranked Trojans will meet for the second time this season and 65th time in their history on Wednesday with USC holding a 37-27 edge in the all-time series. The Trojans snapped a streak of 17 straight CSUN wins with a 25-18, 25-17, 25-20 win at home on Jan. 12. The Matadors are 12-16 all-time against USC in The Matadome but have won the last eight matches between the two teams in Northridge. The Trojans swept a pair of road matches at Stanford and Pacific last week after falling to Pepperdine on Feb. 11 for their only loss. Senior opposite Murphy Troy leads USC in kills averaging 4.64 kpg which ranks second in the MPSF. Senior setter Riley McKibbin leads the MPSF in assists averaging 12.06 per game as the Trojans are hitting a conference-best .390 as a team.
Friday's match between the Matadors and ninth-ranked Waves will be the second meeting between the two teams this season and 70th overall. Pepperdine leads 50-19 in the all-time series which dates back to 1978. Northridge topped the Waves in five sets on Jan. 15 in Malibu to end a string of four straight Pepperdine victories. The Matadors are 10-20 all-time against the Waves in The Matadome. Sophomore opposite Maurice Torres leads Pepperdine in kills averaging 4.11 which ranks fifth in the MPSF. The Waves are hitting .298 as a team.
After a disappointing road loss at No. 8 UC Irvine on Friday, CSUN bounced back to knock off UC San Diego in four sets (18-25, 25-22, 25-19, 25-23) Saturday. Senior Tanner Nua also bounced back from a sub-par outing at UC Irvine by matching his season-high with 13 kills at UCSD. The opposite hit just .171 in a season-high 41 swings but did add two aces, four digs and four blocks. Freshman Greg Faulkner continued his consistent play of late with 11 kills (.353) and six blocks (two solo) while fellow freshman Brandon Lebrock had his best match in nearly a month with 11 kills and a season-best eight digs while hitting .304 in 23 attacks.
Following home matches with USC and Pepperdine this week, the Matadors will wrap up the three-match homestand against UCLA next Wednesday, Mar. 2. A single road match at UC Santa Barbara follows on Mar. 4 before CSUN returns for its longest homestand of the season beginning Mar. 9 with a non-conference match against Loyola-Chicago.


text:
Note:I am not a writer nor a very good documentor, so if this needs some work please let me know, I have read dozens of instructables but never have been able to write my own, I just dont have the knack for it.
I am mostly writing this because I could not find another one like it on instructables, so count this as a springboard.
Step 1: Purchasing Materials
1 Rain Bird 2 1/2in Pop-Up Spray Head (whatever coverage area you want IE 90, 180 or 360)
4 3/4in 90's
2 3/4in Tee's
1 3/4in X
1 3/4 to 1/2in reducer (one half is what is on the bottom of my sprinkler head)
1 3/4 Slip x thread coupling
1 Package of hose washers (to keep it from leaking)
1 10foot stick of 3/4in pipe
A tape measure(optional)
PVC Pipe cutters
Pencil (optional)
PVC Glue
Personally I bought all of my materials at Lowes because I was there and they had all of the materials I need. (Nothing against Home Depot, LOL)
Step 2: Sizing and cutting
Two 10in pieces
Four Five inch pieces
Two 4 1/4in pieces
Two 1in pieces
Size Up:
Assemble all of the parts to make sure they fit , then get the glue ready!!
Note: Glue outside, because of the horrid fumes
Nice one!!!
Thanks for posting your project.


text:
What You Should Know
|Star Rating
|2 or More Patented Ingredients
|Less Than $5 Shipping
|Trial Offer
|Rejuval Skin (2014 Editors Choice)
|Facial Toner
|IQ Derma
|Meaningful Beauty
Although there are countless skin care treatments, cosmetic surgery procedures and oral remedies gracing the current market to potentially improve skin radiance and overall appearance, There is an alternative to these routine methods. It is called Facercise. Even though you may have never heard of this technique, it does exist, and is available online. Carole Maggio is the founder of this facial exercise regimen. Not only are there online classes available, but a book, CDs and DVD sets are sold through the official website as well. A convenient contact page is provided to assist new customers.
Basically Facercise is a series of facial exercises that aim to assist with anything from fuller lips, to lifted eyebrows, to reduced under-eye puffiness, to a more toned jaw line, to a shorter nose, to more open eyes, and even a smoother neck line. This method of anti-aging has been featured in magazines like Marie Claire, Vogue, Health, and the New York Times. In addition to the Facercise exercise techniques, the website also pitches louffas, skin care products and skin care packages. Some of these products are Body Lift, Face Lift to Go, Pore Refinement Cleanser, Creamy Milk Cleanser, Nourishing E Oil, and EGF Repair Syndrome.
Product Details
Facercise is a series of facial exercise routines that are claimed to assist with anti-aging and improved facial features. The online classes that are offered for this method are available via a webcam, however, there is no pricing posted. It appears that all Facercise skin care products can be acquired directly through the website. An example is the Face Lift to Go, which is an enzyme mask that sells for $115. This topical treatment endeavors to exfoliate dead skin cells, while tightening and firming the complexion. The major ingredients incorporated into these skin care products are not revealed.
The Good
- Facercise offers a rather unique approach to skin care and holding onto a youthful appearance.
- Any of the topical skin care products can be attained with ease through the website.
- There is no need to commute in order to take Facercise classes, since they are conveniently offered online.
The Bad
- There is no guarantee that these facial exercises will work as pitched, which means you will likely not get your money back.
- There are no prices posted for Facercise webcam sessions, which is not very convenient.
- Some individuals may not care for all that is involved with this type of skin care or beauty treatment.
- The skin care products that are sold through Facercise are pretty expensive.
The Bottom Line
Naturally the concept of facial exercises is rather unique in comparison to most other approaches to skin care. Some individuals may appreciate the new-age mentality of this and invest in Facercise. Then again, remember that there is no guarantee posted, nor are there any testimonials provided to support Facercise skin care treatments at this time. Finally, in regards to the skin care products that are sold on the official website, none of the key ingredients are mentioned at all.


text:
sounds like a good price for my area at least. i don't have alot of experience with them but they get great reviews. i did put 20 rounds through one at the local range and was impressed for a poly pistol. enjoy your purchase!
Results 1 to 6 of 6
Thread: Beretta PX4 Storm 9mm
Remove Ads
Search tags for this page
9mm largo in beretta px4,
beretta px4 storm 9mm discu,
px4 largo 9mm
Click on a term to search for related topics.


text:
There is provided an articulating tool assembly for performing a mechanical task in a confined area, e.g., applying the torque to install or remove nuts threaded onto machine bolts or other hooks in confined or recessed areas. The articulating tool assembly has an elongated body portion having a handle section and a yoke section, a head portion including a head section and a head retaining section, and an actuation member defining an axle shaft with two spaced apart sprockets. The actuation member is provided for effectuating incremental articulating movements of the wrench head portion with respect to the elongated wrench body portion.
1. An articulation wrench assembly comprising:
an elongated body portion having a proximal handle section and a distal yoke section, the distal yoke section including a pair of yoke arms, each yoke arm including a first engagement area;
a wrench head portion including a wrench retaining section, the wrench retaining section being dimensioned to be received between the pair of yoke arms and including a throughbore having a pair of spaced apart second engagement areas; and
an actuation member movably supported between the pair of yoke arms and including a pair of locking members, wherein the wrench head portion is rotatably supported about the actuation member to facilitate articulation of the wrench head portion in relation to the elongated body portion and the actuation member is movable between the yoke arms from a first engaged position in which each locking member is in engagement with a respective first and second engagement area, to prevent articulation of the wrench head portion in relation to the elongated body portion, to a second non-engaged position in which each locking member is disengaged from at least one of the first engagement area and the pair of spaced apart second engagement areas, to permit articulation of the wrench head portion in relation to the elongated body portion.
2. An articulation wrench assembly according to
3. An articulation wrench assembly according to
4. An articulation wrench assembly according to
5. An articulation wrench assembly according to
6. An articulation assembly according to
7. An articulation wrench assembly according to
8. An articulation wrench assembly according to
This application claims priority from provisional application Ser. No. 60/347,363, filed Jan. 11, 2002, incorporated herein by reference in its entirety.
1. Field of the Invention
The present invention relates to an articulating tool assembly. More particularly, the present invention relates to an articulating tool assembly of the socket driver type having an articulating head portion that is selectively movable into a plurality of angular orientations with respect to a body portion. The present invention also relates to an articulating tool assembly having a body portion including one or more articulating members.
2. Description of the Related Art
It is often necessary to install a nut onto or remove a nut from a machine bolt in a confined area or to perform some other task using a tool in a confined area. For example, conventional ratchet wrenches are not suitable for use in confined areas because restricted access to the confined space interferes with the back and forth motion of the wrench handle or because a mechanic cannot access the confined area in such a way as to transmit the necessary torque to the wrench handle to facilitate the nut installation or removal process. Accordingly, there is a need for a simple, convenient, economical tool, such as a wrench, capable of adapting to use in a confined area to allow a user to operate the tool and perform the necessary tasks, e.g., the removal or installation of nuts.
An object of the present invention is to provide a novel type of articulating tool assembly, which is simple to manufacture and convenient to use. In one preferred embodiment, the articulating tool assembly includes an articulating ratchet wrench assembly including a socket driver.
In accordance with the present invention, the articulating tool assembly has an elongated body portion having a handle section and a yoke section with first and second opposed yoke arms. Preferably, at least one of the yoke arms has a toothed aperture. A head portion includes a head section and a head retaining section having a bore which partly consists of teeth. An actuation member defines an axle shaft with two spaced apart sprockets. The axle shaft extends through the toothed apertures of the two yoke arms and the bore of the head retaining section. In an engaged position, the first sprocket of the axle shaft engages the toothed aperture of the first yoke arm and a first toothed area of the bore of the head retaining section, while the second sprocket engages the toothed aperture of the second yoke arm and a second toothed area of the bore of head retaining portion. In this position, the actuation member prevents articulation of the head portion of the tool assembly in relation to the elongated body portion. In the disengaged position, the second sprocket is rotatably positioned within a raceway area of the bore of the head retaining portion while the first sprocket engages only the toothed aperture of the first yoke arm. In this position, the head portion is free to articulate in relation to the elongated body portion. Alternatively, in the disengaged position, the first sprocket may engage only the raceway area of the bore of the head retaining section while the second sprocket may engage only a toothed aperture of the second yoke arm.
It is envisioned that two or more yoke sections may be provided along the length of the elongated body portion to provide a tool having a plurality of areas of articulation.
Therefore, users can easily utilize the adjustable articulating tool for accessing a confined area by using the articulated movements of the tool head portion with respect to the elongated body portion to perform a desired task, e.g., to tighten and loosen bolts.
The above objects and other advantages of the present invention will become more apparent from the following detailed description taken in conjunction with the accompanying drawings, in which:
A preferred embodiment of the present invention will be described hereinbelow with reference to the accompanying drawings. In the following description, like reference numerals identify similar or identical elements throughout the several views, while well-known functions or constructions are not described in detail so as not to obscure the invention in unnecessary detail. Although this description refers specifically to an articulating wrench assembly, it is to be understood that this disclosure may be incorporated into other tool assemblies, e.g., screw drivers, magnetic retrieval devices, prying devices, hammers, paint brushes, a variety of different medical and/or surgical tools, articulating devices, etc.
Referring to
Referring now to
As seen in
As seen in
Alternatively, as seen in
The two disengaged positions can be selected by manually pushing or pulling on actuation member 30. Actuation member 30 can be pushed or pulled by the user or by other means, such as a mechanism including a biasing spring or a remotely actuated mechanism. For example, a linkage assembly may be provided to facilitate movement of actuation member 30 between engaged and disengaged positions from handle section 13. One preferred embodiment of the linkage assembly illustrated in
It is also envisioned that axle shaft 32 may have protrusions or extensions, e.g., a gripping member or O-ring, at the either or both ends thereof so that the actuation member 30 can be more easily manipulated. In an alternate embodiment, a protrusion or protrusions 60 may be formed and positioned on the wrench retaining section 22 (and/or yoke section 14) to contact an inner wall of yoke section 14, e.g., a rubber surface, etc. Contact between protrusions 60 and the inner wall of yoke section 14 provides a frictional resistance to articulation when the actuation shaft is in the disengaged position to prevent head portion 20 from flopping around in relation to body portion 12. Alternately, a resilient pad may be substituted for protrusions 60 to increase the frictional contact between retaining section 22 and yoke section 14.
It is envisioned that a movable actuator such as described above may be suitable for use in a variety of other types of articulatable devices to control articulation of a component of the device. For example, in one preferred embodiment a hinge 200 shown in
Hinge pin 206 can be manually moved between the engaged and disengaged positions. Alternately, a link 212 can be used to fasten one or both ends of pin 206 to a suitable drive mechanism, e.g., motor, solenoid, etc. Although illustrated as a hinge assembly, the assembly shown in
Although the invention has been described in its preferred form with a certain degree of particularity, variations and modifications may be made therefrom within the scope of the accompanying claims without departing from the principle of the invention and without sacrificing its chief advantages.
Patent Citations
Referenced by
Legal Events
Original Image


text:
New Guestbook Signup
Guestbook Sign In
|Sign In
Click here to view the Game Finder.
New Machines
Hangover – Pretty Awesome
All the iconic imagery, hit music, and main characters from the hilarious film are back in this follow-up to the wildly successful first edition slot game.
The 5-reel, 40-payline game offers four Multilevel Progressives and a Wide-Area Progressive link.
Features stacked symbols and random multipliers in the base game and multiple interactive bonuses:
Three group bonus features:
The Ellen DeGeneres Show™ Video Slots
Your favorite talk show is now your favorite slot machine! Play The Ellen DeGeneres Show™ Video Slots at Bellagio!
Two unique base games capture the essence of The Ellen DeGeneres Show™ with unique features and bonus events:
- The Ellen DeGeneres Show™ featuring Ellen's Dance Party™ Video Slots
- The Ellen DeGeneres Show™ featuring 12 Days of Giveaways™ Video Slots
Four easily recognizable bonus features are available in the two games:
WILLY WONKA Pure Imagination™
Come with us to a world of pure imagination in the form of the latest Gamefield xD™ slot: WILLY WONKA Pure Imagination. This new theme takes the mechanics that players love from previous WILLY WONKA WMS games, adds a unique twist, and then displays them on the seamless screens of the Gamefield xD cabinet for a scrumdiddlyumptious gaming experience.
Collect three or more Golden Eggs in order to trigger the Golden Egg Bonus where each egg collected drops into one of three buckets: the Fizzy Lifting Drink Bonus, the Veruca Salt Bonus, or the Pure Imagination Free Spins. The bonus with the most eggs then plays out. Collect bubbles for credits in the Fizzy Lifting Drink Bonus, open presents for credits in the Veruca Salt Bonus, and watch as Ooompa Loompas push oversized symbols onto the main reel array in the Pure Imagination Free Spins.
The Oompa Loompa Feature may randomly trigger, which stretches the reels up to 15 rows high and can potentially add up to five full WILD reels and up to a 5x multiplier! No WILLY WONKA slot would be complete without the chance to pick chocolate bars at the end of every bonus for up to a $5,000 prize in the Golden Ticket Bonus!
The glitz, glamour and, most importantly, the spectacular music from SIR ELTON JOHN himself is brought to life in this new gaming experience from WMS. The ELTON JOHN theme features dual top screens that peek through his iconic glasses and a Sensory Immersion chair that belts out his legendary hits!
Get a little action in the Saturday Night's Alright for Fighting Bonus where wheels appear on the top screen. Each wedge on the left wheel displays credit awards, spin enhancements or extra spins. The right wheel starts out empty. Spin the left wheel 7 times to collect an enhancement on each spin that transfers to the right wheel. The spins continue until all spins are complete and the right wheel is filled. Then the right wheel is spun for a rockin' win!
Wheels spin to determine the number of free spins in the I'm Still Standing Bonus while adding mystery symbols onto the reels and potentially increasing wins! We think it's going to be a long, long time that players will be talking about the Rocket Man Bonus, which launches rockets across the screen to collide with stars for credit values!
Wheel of Fortune Ultra 3 Reels Duo Wheel
This single-payline version of the classic game offers a three-credit maximum bet, and features the Ultra Wheel Bonus:
Wonder Woman
Are you ready for the magic that Wonder Woman™ can do? Showcasing features which radiate the nostalgia of the classic 1970's show, including 8, 16, or 25 Free Games with extra Wilds, three fantastic Progressive levels, Expanding Wilds, and Mystery Stacks, Wonder Woman™ Gold & Wild is here to make her mark loud and true!
The Rolling Stones
Hot Licks will spill from the Rolling Stones Slot Machine, putting players in the front row with the world's greatest rock 'n' roll band!
The themed fascia is instantly recognizable, and the game itself is endlessly entertaining. Players will settle into the immersive iChair and experience 5.1 Surround Sound while their favorite songs play through the sound track and animation on the interactive screen spin and merge into concert footage. It's a whirlwind of iconic rock, begging players to go on a roll with four interactive features!
Monopoly Luxury Diamonds
This stepper product pairs the classic MONOPOLY™ board with the jackpots that mechanical players love. Three WHEEL symbols trigger the MONOPOLY Wheel Bonus where players spin the wheel to land on one of the board game's iconic properties. Before the wheel spins, pick one of five cards for a variety of enhancements including 2x multipliers or even the option to respin the wheel!
Each wedge awards a credit value, or land the wheel on the Free Parking wedge to win the secondary progressive!


text:
Twenty-two guitars placed in the hands of artists have been transformed and will be auctioned to support Music on the Square, Jonesborough's Friday night mini-festival.
The fundraiser, the third annual Spring Tune-Up, will be held at the International Storytelling Center Friday, April 5 from 6 to 10 p.m.
Organizer Steve Cook calls the embellished instruments Guit-Art. Exhibiting a wide range of talent, media and imagination, the guitars are now on display at shops in downtown Jonesborough.
Though they do not have to be playable, some of the artists wanted to leave their stamp without disabling the instrument.
Of the entries, Cook is not surprisingly partial to the piece created by his wife Tava with help from Steve and grandson Davis Gunnin. The theme of the piece is "A Thousand Points of Light." It is lit from the inside with two CFL bulbs and covered in painstakingly cut and placed pieces of glass. Davis made the glass tuners and the borosilicate glass rods that protrude from the guitar body.
The quickest turn-around came from artist Terry Warner. "He had it the least amount of time," Cook said, adding. "This guitar belongs at Down Home." Warner has created a three-dimensional audience, stage and musicians from wood veneer and copper wire. Also included is a likeness of his dog Hank.
Beverly Jenkins, co-owner of Main Street Cafe, does mosaics on the side. She has created an intricate mosaic landscape in blues and greens with red accents.
Dave Campbell of Morrell Music donated the 24 classical guitars as part of his Music on the Square sponsorship. In August, three days after receiving the guitars, Cook said all had been claimed by artists, with two being held in reserve. "Two are going to be auctioned as actual guitars to be given to needy students," he said.
The youngest artist to participate is 10-year-old Grayson Smith. According to his mentor, CanJoe John, "Grayson chose acrylic paint as his medium to render the New York City scape, the buildings and the Statue of Liberty, and I then added the surreal sky, touched up a little on the Ellis Island and painted the background and ocean to finish the work."
Grayson's guitar is on display at The Crafty Peddler in the Mail Pouch building across from the old Courthouse.
Bidding should be lively as Allen Brasington auctions the guitars and other items, including a Stressless chair from Mauk's. Cook said no reserve has been set for the guitars, but he hopes the live auction will encourage competition among bidders.
Heavy hors'doeuvres and beer from Depot Street Brewery will be served. Tickets are $20 in advance, available at Jonesborough Art Glass, the Historic Jonesborough Visitors Center, the International Storytelling Center and Morrell's Music in Johnson City. Tickets will be $25 at the door.
MOTS kicks off its 15th season May 3 with the Jonesborough Novelty Band and runs Friday nights through September.
For more information, visit Music on the Square on Facebook or www.musiconthesquare.com.


text:
by Julie Larson
Will Having Keyword Rich Domains Improve SEO?
Because this question has been coming up a lot lately from some of our clients, I thought I'd address it here in a blog post. Like many questions asked of us, the answer to this one is – it depends. Just having a keyword rich domain that is forwarded to your main website, will not provide you with any SEO (search engine optimization) benefits as a domain that is not hosted with a website on it will not be found in the search engines. The only benefit you could experience would be if your keyword rich domain was one that people would type into the url address bar – not search it – but go directly (more…)


text:
Music Love Army to issue protest remixes
The N.C. Music Love Army will release the first of several planned remixes of their recording "We Are Not for Sale: Songs of Protest," produced last year in response to General Assembly policies related to voting rights, teacher pay and other issues.
The new recording, titled "The Remix Army: Volume 1," will be released June 23. The new recording has four remixes of songwriter and Carolina Chocolate Drops member Rhiannon Giddens' a cappella tune "We Rise." The N.C. Love Army asked for remixes of Giddens' song, and four of those arrangements (in addition to Giddens' original) are included on the new disc. Artists who remixed Giddens' song are Raleigh multi-instrumentalist and disc jockey DJ FM, Raleigh band Righteous Fool, electronic music group Christian Desnoyers of Belgium, and Spazm of England.
Composer Alex Kotch of Durham, whose music includes his electro-acoustic dance piece "Alleys of Your Mind," approached the musicians of the Love Army about remixing the tunes using more dance-oriented rhythms and other effects. Christian Desnoyers and DJ FM transform Giddens' song into percussive dance tunes, whereas Righteous Fool adds Jimi Hendrix-style guitar lines to her vocals. Spazm's remix uses echo, giving the song a haunting effect. Giddens is accompanied on vocals by Pura Fé Crescioni and Charly Lowry.
More remixes are in the works, according to the Music Love Army's website. Organizers are seeking remixes to "My Body Politic," written by violinist and songwriter Caitlin Cary and poet-songwriter Shirlette Ammons.
Members of the Music Love Army performed some new protest songs, as well as songs from "We Are Not for Sale," at Monday's Moral Monday event, and will perform again during the June 23 rally.
Cary and musician Jon Lindsay co-founded the N.C. Music Love Army to express solidarity with the Moral Monday movement, which protested the legislature's policies on public education, "fracking," Medicaid expansion and other issues. Cary and Lindsay heard musician Django Haskins' song "We Are Not for Sale" and corralled a group of North Carolina musicians to write and produce a collection of protest songs. Many of the musicians had already attended or performed at several Moral Monday protests. The musicians performed an open rehearsal last summer at The Pinhook in Durham, then recorded the 10-song collection in Raleigh. The album was released in November.
Among the other artists who contributed to the original recording were Lynn Blakey ("Army of Love"), Billy Sugarfix ("Abraham Lincoln in His Grave") and Laurelyn Dosset ("My Beloved Enemy").
Proceeds from the original album and from live performances went to Progress North Carolina and Planned Parenthood of Central North Carolina.
For information about this release, visit ncmusiclovearmy.org


text:
Residents vow to fight bid to build wind turbines at former RAF Binbrook in Lincolnshire
Posted: November 30, 2012|
New plans have been unveiled for two wind turbines on the site of an iconic Lincolnshire airbase.
The controversial scheme is proposed for the former RAF Binbrook in the heart of the picturesque Wolds.
The application comes weeks after Energy Minister John Hayes spoke out about the growing number of onshore wind farms which are being "imposed on communities".
But he was last week contradicted by coalition colleagues led by Prime Minister David Cameron, who insisted each application would be considered on its own merits.
Related content
Scottish-based Caledonia Wind Power Ltd wants to put up two 25m structures on the former RAF Binbrook – which is now an industrial estate close to Brookenby village.
A consultation exercise has been launched by West Lindsey District Council and residents said they would fight the scheme.
Roger Beecroft of agents Aska Energy confirmed that the turbines – which would generate enough power for at least 646 houses – would be located "as far from other houses as possible" if the scheme goes ahead.
"These turbines are relatively quiet and noise levels experienced at nearby residences will be below 35 decibels, the background noise effectively masking that produced by the turbines," Aska said in its application document.
"The nearest house is 400m from the turbines which is at the end of Cambridge Crescent."
Natural England confirmed that the application fell within the Lincolnshire Wolds Area of Outstanding Natural Beauty – but did not think it would impact on the landscape.
But local residents disagree.
"If there isn't already a petition up against this then I'll make sure there will be," said Chichester Road resident Jude Brown, administration co-ordinator at CK Polymers on the Binbrook Technical Park.
"This would be just around the back of my house and I just can't believe anyone would want to put wind turbines there.
"We moved here 19 years ago, not long after the houses were sold off by the RAF.
"Many people like me think it's a beautiful place – but it won't be if this is allowed."
Former Brookenby parish councillor Andrew Robinson is a senior education manager who lives in Cumberland Terrace.
"There will be major opposition to this because it's in the Lincolnshire Wolds and many people will definitely object," Mr Robinson said.
"They would cause a lot less disruption than 50 or 60 jets used to when it was an airbase, but this will not be welcomed."
Developers of a scheme for 10 massive 400ft turbines proposed for Hemswell Cliff – between Gainsborough and Market Rasen – were given a three-months' extension on their preparations last month.
And an even larger wind farm of 17 turbines of a similar size put forward for Yawthorpe near Gainsborough last year has not reached submission to the district council stage as wind measurements are taken from a temporary mast.


text:
Our last Transit of Venus is a film project about the Transit of Venus 2012, supported by the European Planetology Network (Europlanet, europlanet-eu.org).
Please visit vimeo.com/channels/ourlasttransitofvenus for other related videos.
A Transit of Venus is when planet Venus passes in front of the Sun as seen from the Earth. This happens at intervals of 121.5, 8, 105.5, 8, 121.5, 8, etc. years. Transits of Venus were observed in 1639, 1761 and 1769, 1874 and 1882 and in 2004. After 2012, one will have to wait until 2117 to see another one.
It was realised in the past that a Transit of Venus event observed from different places on Earth could lead to a direct measurement of the size of the Solar System. The events in the 18th and 19th century led to worldwide expeditions to do exactly that.
In 2004, the exercise was repeated by amateur astronomers and students. Scientists used the Transit to learn more about the atmosphere of planet Venus and about how to observe exoplanets transiting their mother stars. In 2012, similar actions will be organised all over the world.
The film is in the make at the moment and we are now getting footage of the aftermath of the event, the science results and people's memories.
More information on the Transit of Venus 2012 can be found on transitofvenus.nl, transitofvenus.info, sunearthday.nasa.gov/2011/index.php and imcce.fr.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?


text:
Vintage hairstyles are so much fun simply because they are both elegant and stylish. If you're seeking a new look for spring, but aren't digging any of the current trends (crazy colors, over sized afros, half-shaved heads, etc) then perhaps seek inspiration from the past. Take a blog break and peep how top A-listers rock retro styles from the 20's, 30's, 40's, 50's, and 70's! My favorites looks include Rihanna's curly mop, Christina's bouffant, Brandy's finger waves. Gwen's curly bob, Beyonce's pin curls, Iman's chocolate cascading waves, Zoe's messy bun and more!
Vintage Hairstyles: 13 Celebrities Rock Pin Curls and Curly Bobs


text:
Hi All,
You see most of my friends and relatives are not in computers. For them I am just a person who works in computers. Now when they see the NANY 2011 MUG on my table, they pleasantly ask about it. No matter how I try to boost or convince them that I WON it, they look suspiciously at me. Since there is no mention of my name or my contribution, they do not take my words for it. Showing them the websites and my photos on them is easier said than done. Since they are not in computers, they understand nothing, forget about specify programming.
I was just wondering what can be done so that to make it legitimate. One thought came was to have a 'certificate' beside the mug.
I think if we can make a certificate of the sort "This to certify that Mr/Ms [Name] has participated in NANY 2011 by contributing [1. Apps], [2. Apps] etc. and so on". This certificate we can make as pdf downloadable with NANY logo, ribbon etc., which the members can download and print.
Well hope you got my point. Any other idea is also welcome.


text:
Change currency:
Other country sites
Your Recent Searches
Your bag is empty
Free DELIVERY Worldwide*
Originally released in the 80s, Ray-Bans iconic Clubmaster sunglasses keep it timeless with their 50s browline-inspired design. Give a nod to nostalgia with classic tortoiseshell frames or update the pop-culture favourites with coloured lenses and printed arms.
Refine By
Price Range
The celebrities named or featured on asos.com have not endorsed recommended or approved the items offered on site
©2015 asos.com Ltd
All rights reserved
Cookie Use
ASOS uses cookies to ensure that we give you the best experience on our website.
If you continue we assume that you consent to receive all cookies on all ASOS websites.


text:
As a Wellmark member, you are enrolled in Blue365®, a program that offers discounts and savings on a variety of health and wellness services and products. View daily deals and learn more about Blue365 at Wellmark.com/HealthyDeals.
Take a back-to-basics appproach to exercise.
© Wellmark Inc. All Rights Reseved.
Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association doing business in Iowa and South Dakota.
Privacy & Legal | Browser Information


text:
Register now for free, or sign in with any of these services:
We signed Warren Moon? Same age as Shaq?
Rucker has talent but he needs to be in better condition. He had a couple of chances late in the preseason game against the Jets where he was so tired, he couldn't extend his arms and catch winning TD.
Please, can training camp start soon? These posts are killing me.
Sgt. Spicer is from ZANESVILLE, OHIO. Could someone please correct this.
I'm 41 and a traditionalist who grew up on sour kraut, pork, bowl games, and especially the Rose Bowl at 5pm on New years Day. However, the time has come for a playoff. I love the bowls, but to do it right, they must go to a format more of the Division III way.
Suspended sentence, case closed. Let's have some common sense here., unless... does the fawns mother have any ties to Jimmy Dimora?...
Check out former Cuyahoga County JFS directors...
You don't have a record of phone calls reporting abuse at JFS? Pumper and Dimora are both (soon to be) felons. McCafferty needs to be the next one investigated. This is disgusting,
She's still hot!
When does training camp start in Berea?
Went to the game Saturday night and enjoyed watching football again. However, if this is what we Cleveland fans have to hang our hats on for the rest of the year, I need a hobby.
Hey tired1023, quit sending the same uneducated post 3 times. We get the point. Dimora is a crook!
Which ward covers the Dawg Pound? He fit in there (at least until the end of 3rd quarter when beer sales are cut off).
An eye for an eye would be nice in this case-in other words, torch the moron- however, I'd say in approx 14 hours, this peice of filth will burn...in hell! Enjoy the well done steak. Hopefully the look will get you use to your eternity with Satan.
This is embarassing to say I once lived and went to school in Akron.
I guess parents had already tried taking Play Station away? Maybe I'll try this new parenting trick with my 15 year old son.
Oh no, now Coach Leach from Texas Tech is really going to be peed off! I'm sure Mangini is shakin in his shoes! My guess is there's more to the story about why this clown (Leach) almost lost his job down there at Tech. What an idiot.
As a season ticket holder, I'd have to say last year was more frustrating then any other since I've starting attending games in 1977. Apathy had set in. With that said, I'm somewhat pleased with Mangini and how he's running things. It reminds me of Belichick back in the early 90's. I could care less if I get "scoops" out of Berea every day. Give the guy a chance.
Where is Boss Hog, Roscoe P. Coltrain, and Uncle Jessie? Are you sure we're not in Hazzard County?